 Aspirin is commonly used by kidney transplant recipients to reduce the risk of heart attack and stroke. However, it can also increase the risk of bleeding, especially in those who have recently undergone surgery. This study found that aspirin reduces the risk of allograft failure, allograft thrombosis, and major adverse cardiac events or death in kidney transplant recipients, but does not affect the risk of allograft rejection or delayed graft function. Further research is needed to determine whether the potential benefit of aspirin outweighs the risk of bleeding in specific kidney transplant patient populations. This article was authored by Wizard Chumpasiporn, Charathong Praen, Donald G. Mitema, and others.